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Spirometer D Body Box Z VW Beetle D Mercedes?In this issue of Respiratory Medicine, a group of pulmonary
specialists from Germany have provided a much-needed
review of the principles and practice of body box measure-
ments and clinical interpretation of the results.1 This
excellent review should provide the foundation for a new
practice guideline for the measurement of specific airway
resistance (sRaw). Almost every hospital-based pulmonary
function testing laboratory (PFT lab) has a bodybox (orwould
buy one if they could afford it). The clinical application of
body box tests began sixty years ago andmillions of body box
tests are done worldwide for clinical purposes (along with
spirometry tests) each year. The value of body box tests for
confirming restriction in patients with a low vital capacity;
and hyperinflation and reduced sRaw in patients with asthma
or COPD has never been questioned. But it should be.
There is actually a paucity of evidence that adding body
box measurements to spirometry, DLCO, and chest X-ray
results adds clinical value for detecting obstructive or
restrictive types of lung disease or for the differential diag-
nosis of chronic dyspnea. Spirometry remains the gold stan-
dard for detecting the intermittent airflow limitation of
poorly-controlled asthma and the O in COPD. When spirom-
etry shows airway obstruction, a abnormally high sRaw (or
abnormal forced oscillation technique, FOT, results) perhaps
increases confidence that the patient really has airway
obstruction. Such concordance occurs about 80% of the time
(and body box results are then just “frosting on the cake”).
But when spirometry and body box results are discordant,
most experts interpreting the PFTresults just ignore thebody
box results, perhaps because the upper limits of the sRaware
not as well established as for FEV1/FVC.
In theory, changes in sRaw might be more sensitive for
changes in airway obstruction than changes in FEV1.
Certainly the percentage change in sRaw is usually larger
than the percent change in FEV1. However, short-term
changes in FEV1 (pre- and post-bronchodilator, or from
visit-to-visit for a patient being treated for an obstructive
lung disease) are considered more reliable than changes in
airway resistance because the “noise of measurement”
(coefficient of variation) is much higher for sRaw and RawDOI of original article: 10.1016/j.rmed.2011.02.006.
0954-6111/$ - see front matter ª 2011 Elsevier Ltd. All rights reserved
doi:10.1016/j.rmed.2011.03.011when compared to FEV1.
2 In addition, studies which esti-
mate the minimal clinically-important change in sRaw (or
FOT indices) have not been published.
For inhalation challenge tests done in an attempt to
change the pre-test probability of asthma, the American
Thoracic Society PFT experts recommended against the use
of sRaw3 because the deep inhalations needed to measure
the FEV1 increase the sensitivity and specificity of the test
when compared to the relaxed tidal breathing used to
measure sRaw (or FOT). That’s becausepatientswith twitchy
airways (due to asthma) lack the bronchodilator response to
a deep inhalation seen in people with healthy airways.4
About 10% of patients cannot perform good quality
spirometry tests, even when coached by a skilled technolo-
gist. The rate is higher in pre-school children and patients
over age 80. Mild airway obstruction may be obscured if they
cannot exhale until a volume-time plateau is reached
(causing the FEV1/FVC to be over-estimated). However, in
moderate to severe airway obstruction, the bowl-shape of
the flow-volume curve can be recognized even if the patient
quits too soon. Changes in FEV1 may be unreliable if the
patient cannot produce at least two repeatable FEV1s (within
150 mL); measurement of sRaw (or FOT) to confirm
obstruction (or the effect of interventions)may thenbemore
reliable than spirometry in such patientse if an experienced
and skilled technologist (who can recognize and reject arti-
facts) makes the measurements and a strict quality assur-
ance program is in place.5
Body plethysmography also enables relatively rapid meas-
urements of static lung volumes (when compared to helium
dilution and nitrogen washout techniques). The hyperinflation
which usually accompanies airflow limitation can be detected
by a high residual volume (RV) and high RV/TLC. On the other
hand, the degree of hyperinflation is directly associated with
the degree of airway obstruction (as measured by percent
predicted FEV1), in both asthma and COPD.
6 Studies have not
yet beendone todemonstrate that knowledgeof thepresence,
severity, or change in hyperinflation adds any clinically useful
information to spirometric measurements of FVC, slow VC, or
inspiratory capacity (IC). The ATS/ERS 2005 PFT guidelines did
not even attempt to define hyperinflation, overdistention,
trapped air volume (TAV), or “pendelluft”.7 In addition, the.
958 Editorialupper limit of the normal range for RV/TLC and TAV are poorly
established, since only one or two studies have ever measured
spirometry, lung volumes, andDLCO from the healthy subset of
a population-based sample of adults or children.
What about restriction? Only about half of the patients
with spirometric restriction (a low FVC but a normal FEV1/
FVC) referred to a PFT lab have a low TLC (true restriction
according to the ATS/ERS PFT guidelines) e whether lung
volumes are measured using a body box or a gas dilution or
washout technique. The others are categorized as having
a “non-specific pattern”. The only study ever done to char-
acterize patientswith this non-specific pattern found that on
average, they have a wide variety of conditions (including
obesity)8 and a generally benign clinical course.9 On the
other hand, TLCpleth is not sensitive for detecting interstitial
lung disease (ILD): a large number of patients with an ILD,
obvious ona lungHRCT,haveanormal TLC. Some ILDpatients
have a low DLCO or a low static lung compliance (Cst),10 but
when was the last time that you can remember asking
a patient to swallow an esophageal balloon for a lung
compliance test? Astute clinicians rely on lung HRCT exams
and biopsies (not TLC) to detect and confirm ILD. Regulatory
agencies require that treatment efficacy of new drugs for
idiopathic pulmonary fibrosis are based on increases in FVC
and/or DLCO, not changes in TLC.11
Well-designed studies are needed to confirm the theory
that body box measurements add clinically-important
information in some situations. Meanwhile, a VW bug will
get you from here to there as well as a Mercedes convert-
ible (but not in the same style or speed). I love German
engineering, so I compromised and drove a Karmann Ghia
while in medical school, residency, and fellowship training.
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